Consensus Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-01-14 pm EST			5-day change	1st Jan Change
218.55 ^USD	+2.29%		+5.33%	+5.61%

Jan. 14	Tecvayli monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide	RE
Jan. 14	Johnson & Johnson Reports 71% Risk Reduction for Tecvayli in Phase 3 Myeloma Study	MT

Evolution of the Average Target: Johnson & Johnson

Evolution of the Target Price: Johnson & Johnson

Changes in Analyst Recommendations: Johnson & Johnson

900c9eae4dfb004680f8ef055e0.emq20MqDuX0yzygzruVSgmIaZmX9fch6eSSirb6W0-Q.DibssbrI-hZlt35rmpYKwCN2IROHO5EKT3LXz4nesK01IOW5ms7sDHWuaQ~090a4526f70aa8871af053e056833d4a

Analysts' recommendations: Johnson & Johnson

Jan. 09	Bernstein Adjusts PT on Johnson & Johnson to $208 From $193, Maintains Market Perform Rating	MT
Jan. 07	Stifel Adjusts Price Target on Johnson & Johnson to $205 From $190, Maintains Hold Rating	MT
Jan. 05	Wolfe Research Adjusts PT on Johnson & Johnson to $240 From $225, Maintains Outperform Rating	MT
Dec. 30	Barclays Adjusts PT on Johnson & Johnson to $217 From $197, Maintains Equalweight Rating	MT
Dec. 18	Goldman Sachs Adjusts Johnson & Johnson Price Target to $240 From $213, Maintains Buy Rating	MT
Dec. 17	RBC Lifts Price Target on Johnson & Johnson to $240 From $230, Maintains Outperform Rating	MT
Dec. 15	Johnson & Johnson Remains Stable With Modest Growth Potential, BofA Says	MT
Dec. 12	Wells Fargo Adjusts Price Target on Johnson & Johnson to $230 From $212, Maintains Overweight Rating	MT
Dec. 12	Morgan Stanley Adjusts PT on Johnson & Johnson to $197 From $190, Maintains Equalweight Rating	MT
Dec. 11	Johnson & Johnson Positioned for Growth on Multiple MedTech and Immunology Catalysts, RBC Says	MT
Dec. 11	RBC Raises Price Target on Johnson & Johnson to $230 From $209, Keeps Outperform Rating	MT
Dec. 11	Citigroup Adjusts Price Target on Johnson & Johnson to $232 From $215, Maintains Buy Rating	MT
Dec. 10	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT
Dec. 10	HSBC Adjusts Price Target on Johnson & Johnson to $240 From $215, Maintains Buy Rating	MT
Dec. 05	Guggenheim Adjusts Price Target on Johnson & Johnson to $227 From $206, Maintains Buy Rating	MT
Dec. 01	Barclays Adjusts Price Target on Johnson & Johnson to $197 From $176, Maintains Equalweight Rating	MT
Nov. 17	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Nov. 13	Scotiabank Initiates Johnson & Johnson at Sector Outperform With $230 Price Target	MT
Nov. 07	America's markets lose their nerve
Nov. 06	Relay Therapeutics, Inc. Appoint Board and Committee, Effective November 4, 2025	CI
Nov. 06	J&J says FDA approves Caplyta as add-on depression treatment	RE
Nov. 05	Recursion Pharmaceuticals, Inc. Announces Management Changes, Effective January 1, 2026	CI
25-10-27	Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial	MT
25-10-27	Johnson & Johnson's Study Shows Clinically Meaningful Results for Icotrokinra in Ulcerative Colitis Patients	MT
25-10-27	Johnson & Johnson Announces Week 28 Results from Phase 2b ANTHEM-UC Study of Icotrokinra	CI

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	JOHNSON & JOHNSON					-3%
	ELI LILLY AND COMPANY					+4.01%
	ABBVIE INC.					+10.23%
	ROCHE HOLDING AG					-2.56%
	ASTRAZENECA PLC					+5.65%
	NOVARTIS AG					-5.45%
	MERCK & CO., INC.					+2.09%
	NOVO NORDISK A/S					+3.38%
	AMGEN INC.					+0.8%
	GILEAD SCIENCES, INC.					+8.15%
	Average					+2.33%
	Weighted average by Cap.					+2.27%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

218.55USD

Average target price

212.00USD

Spread / Average Target

-3.00%

High Price Target

240.00USD

Spread / Highest target

+9.81%

Low Price Target

155.00USD

Spread / Lowest Target

-29.08%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Bernstein
Stifel Nicolaus
Wolfe Research
Barclays
Goldman Sachs
RBC Capital Markets
Wells Fargo Securities
Morgan Stanley
Citigroup
HSBC
Guggenheim
Scotiabank
Rothschild & Co Redburn
Daiwa Securities
BofA Securities
Argus
Leerink Partners
Raymond James
JPMorgan Chase
TD Cowen
UBS
DBS Bank
Redburn Atlantic
DZ Bank
Atlantic Equities
Credit Suisse
SVB Securities LLC
DA Davidson
SVB Financial
Sanford Bernstein
Cantor Fitzgerald
J.P. Morgan Chase
Cowen
SVB Leerink
RBC	Brandon Henry